Another drug from Beam Therapeutics, BEAM-302, entered the clinical trial stage in 2024 and is set to correct the mutation in the alpha-1 antitrypsin gene, leading to the expression of the p.Glu366Lys form, which misfolds and aggregates inside liver cells, causing liver damage and alpha-1 antitrypsin deficiency (AATD) [132]. This evidence concerns the gene SERPINA1 and Alpha-1-antitrypsin deficiency.